A Narrative Review of BPC-157 for Musculoskeletal Healing Evaluated BPC-157's molecular mechanisms and therapeutic potential for musculoskeletal injuries including tendons, ligaments, and cartilage, noting promising preclinical results and discussing the safety profile relevant to clinical translation (Curr Rev Musculoskelet Med, 2025)
[] Results from clinical investigations have been inconsistent
[3] That is a genuine Phase 3 result but it belongs to the combination, and it was measured against placebo, not against tirzepatide
Additionally, early indicators show benefits in cardiovascular markerspositioning these therapies as more than just glucose-lowering agents
The substantia nigra isnt traditionally considered a primary serotonergic center (that distinction belongs to raphe nuclei), yet BPC-157s consistent elevation of serotonin there suggests a unique therapeutic approach
doi: 10.1007/s10495-021-01687-9 192 PereiraJFJordanPMatosP